Prometheus Biosciences, Inc. (NASDAQ:RXDX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDXGet Rating) have been given a consensus recommendation of “Buy” by the ten analysts that are covering the company, MarketBeat reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the stock in the last year is $60.10.

Several equities analysts recently weighed in on the company. SVB Leerink increased their target price on Prometheus Biosciences from $55.00 to $60.00 and gave the stock an “outperform” rating in a research report on Friday, August 12th. Royal Bank of Canada increased their target price on Prometheus Biosciences from $45.00 to $61.00 in a research report on Friday, August 12th. Piper Sandler increased their target price on Prometheus Biosciences from $53.00 to $67.00 and gave the stock an “overweight” rating in a research report on Sunday, August 28th. Guggenheim increased their target price on Prometheus Biosciences to $75.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 27th. Finally, Wells Fargo & Company increased their target price on Prometheus Biosciences from $51.00 to $71.00 and gave the stock an “overweight” rating in a research report on Monday, August 29th.

Institutional Investors Weigh In On Prometheus Biosciences

Large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC acquired a new stake in shares of Prometheus Biosciences in the first quarter valued at about $31,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Prometheus Biosciences in the first quarter valued at about $86,000. Amundi acquired a new stake in shares of Prometheus Biosciences in the second quarter valued at about $100,000. Amalgamated Bank acquired a new stake in shares of Prometheus Biosciences in the first quarter valued at about $143,000. Finally, Prospera Financial Services Inc acquired a new stake in shares of Prometheus Biosciences in the first quarter valued at about $156,000. Institutional investors and hedge funds own 74.22% of the company’s stock.

Prometheus Biosciences Stock Down 5.3 %

Shares of NASDAQ:RXDX opened at $55.14 on Wednesday. The company has a quick ratio of 13.32, a current ratio of 13.32 and a debt-to-equity ratio of 0.07. Prometheus Biosciences has a 52-week low of $21.50 and a 52-week high of $59.26. The stock’s fifty day simple moving average is $44.26 and its 200-day simple moving average is $36.80. The company has a market capitalization of $2.26 billion, a P/E ratio of -17.50 and a beta of 2.30.

Prometheus Biosciences (NASDAQ:RXDXGet Rating) last issued its quarterly earnings data on Thursday, August 11th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.06. Prometheus Biosciences had a negative return on equity of 54.91% and a negative net margin of 1,700.51%. The business had revenue of $1.27 million for the quarter, compared to the consensus estimate of $0.70 million. As a group, equities research analysts forecast that Prometheus Biosciences will post -3.49 earnings per share for the current fiscal year.

About Prometheus Biosciences

(Get Rating)

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.

Featured Stories

Analyst Recommendations for Prometheus Biosciences (NASDAQ:RXDX)

Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.